Arcturus Therape Stock Price, News & Analysis

Arcturus Therapeutics (NASDAQ: ARCT) will release its financial results for Q1 2022 on May 9, 2022, after market close. A conference call and webcast will follow at 4:30 PM EDT. The company, based in San Diego, California, focuses on developing mRNA medicines for infectious diseases and rare liver and respiratory conditions. Key collaborations include partnerships with prominent pharmaceutical companies and institutions.

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has granted stock options totaling 60,400 shares to four newly-hired employees, as approved by its Board of Directors. The options have an exercise price of $25.24 per share and will vest over four years. This grant is part of the Nasdaq Rule 5635(c)(4) inducement exception, aimed at aiding in employee recruitment. Founded in 2013 and based in San Diego, Arcturus focuses on developing messenger RNA medicines for infectious diseases and rare liver and respiratory conditions.

Arcturus Therapeutics announced positive topline data from its ongoing Phase 1/2/3 trial for ARCT-154, a self-amplifying mRNA vaccine against COVID-19. The study demonstrated 95% efficacy in preventing severe disease and 55% efficacy against symptomatic cases. Conducted in Vietnam during the Delta and Omicron variant dominance, the trial enrolled over 19,000 adults, with comparable adverse events to placebo. Following this success, ARCT-154 will advance into a pivotal booster trial, signaling a significant step for the company's mRNA platform and future vaccine development.

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced that CEO Joseph Payne will participate in the "RNA Therapeutics in Rare Diseases" panel at the Cantor Fitzgerald Virtual Rare Disease Summit on March 29, 2022, at 2:45 p.m. ET. This event highlights Arcturus' commitment to RNA medicines, particularly in infectious disease vaccines and rare liver and respiratory diseases. The company, based in San Diego, has a diverse pipeline of mRNA vaccine programs, including those for COVID-19 and cystic fibrosis, supported by innovative delivery technologies and strategic partnerships.

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) announced the approval of inducement stock options totaling 20,000 shares for two newly-hired employees. The options have an exercise price of $20.89 per share, aligning with the stock's closing price on March 16, 2022. These options will vest over four years, with 25% vesting after one year and the remainder monthly over the subsequent 36 months. This grant is part of the company’s efforts to attract talent as it focuses on developing mRNA medicines for infectious diseases and rare liver and respiratory diseases.

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has announced management participation in a Fireside Chat at the Barclays Global Healthcare Conference on March 16, 2022, at 1:35 p.m. ET. This event will provide insights into the company's late-stage clinical programs focusing on mRNA medicines, including vaccines for infectious diseases and treatments for rare liver and respiratory diseases. A live webcast will be available, with an archived replay accessible for 90 days. For more details, visit ArcturusRx.com

Arcturus Therapeutics Holdings Inc. has submitted an Emergency Use Authorization (EUA) application for ARCT-154 to the Vietnam Ministry of Health. Clinical data show 28- and 54-fold increases in neutralizing antibodies against SARS-CoV-2 ancestral and Omicron strains, respectively. Financial results for Q4 2021 reveal total revenue of $5.8 million, marking an increase from $2.2 million in Q4 2020. However, the company reported a net loss of approximately $38.7 million for the same period. Cash reserves stand at $370.5 million, expected to sustain operations into late 2023.

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) announced the grant of stock options for 11,200 shares to three new employees as part of their employment compensation. The options, priced at $24.85 per share, are granted under the Nasdaq Rule 5635(c)(4) inducement exception. These stock options will vest over four years, with 25% vesting after one year and the rest monthly over the subsequent three years, contingent on continued employment. This move supports Arcturus's commitment to attract top talent in the competitive biotech landscape.

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) will announce its financial results for the quarter and year ended December 31, 2021, after market close on February 28, 2022. A conference call and webcast will follow at 4:30 PM EST on the same day. The company specializes in developing mRNA medicines, focusing on vaccines for infectious diseases and rare liver and respiratory diseases. Arcturus leverages unique technologies, including LUNAR® lipid-mediated delivery and STARR™ mRNA Technology, in its diverse pipeline targeting various conditions including COVID-19 and cystic fibrosis.